Dimole

Quick links to important sections

Dimole

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dimole

Property Description
Active ingredient Dipyridamole
Form Tablet, Injectable solution, Extended-release capsule
Pharmacological class Antiplatelet agent and Vasodilator agent
Common use Thromboembolism prophylaxis and Cardiac stress testing
Origin Synthetic (Pyrimidopyrimidine derivative)

Dimole is a systemic prescription medication whose active component is Dipyridamole, a synthetic compound classified as both an antiplatelet agent and a vasodilator agent. The drug belongs to the pyrimidopyrimidine chemical class. As an antiplatelet agent, its function is to intervene in the process of platelet aggregation, which is the clumping of blood cells that can lead to the formation of harmful clots. Its crucial dual role as a vasodilator agent means it also helps relax and widen specific blood vessels, particularly the coronary arteries. This combined activity provides a unique pharmacological approach compared to simpler single-mechanism drugs.


The General Purpose of Dipyridamole

The general purpose of Dipyridamole is to assist in the management of cardiovascular conditions, primarily by preventing blood clot formation and aiding in specific diagnostic tests. By discouraging platelets from sticking together, the medicine is routinely utilized for thromboembolism prophylaxis in high-risk patient populations. It is indicated for use as an adjunct in the prevention of thromboembolic complications associated with cardiac valve replacement. This means the medication is clinically recognized for helping prevent dangerous clots from forming around replaced heart valves.

Furthermore, its vasodilatory effect is specifically leveraged when the drug is employed as a cardiac stressing agent in certain diagnostic procedures. This confirms its important role in helping doctors assess blood flow to the heart muscle during specialized diagnostic tests.


Dimole Forms and Administration Types

Dimole (Dipyridamole) is manufactured in several pharmaceutical forms, including tablets for oral consumption and a solution for intravenous injection. The difference in form dictates the route of administration; the tablet is used for oral administration, while the injectable solution is used for intravenous administration, typically in a clinical setting. While Dimole is often a single-ingredient product, the active substance dipyridamole is also commercially formulated in extended-release capsule formats as part of a combination product with other antiplatelet medications. This combination product type represents the most frequent contemporary use of Dipyridamole in stroke prevention.

Regulatory References

  1. antiplatelet agent and a vasodilator agent
  2. NCBI StatPearls
  3. MedlinePlus Drug Information

What side effects are possible with Dimole?

Possible Side Effects and Safety Information

The safety profile of Dimole (Dipyridamole) is based on official classifications documented by regulatory authorities, which categorize adverse reactions by frequency and affected organ system. This information is descriptive and does not constitute medical advice or instructions for use.

Frequency-Classified Adverse Reactions

Side effects are commonly categorized based on how frequently they were observed in clinical trials and post-marketing surveillance:

  • Very Common: Adverse effects occurring in more than 1 in 10 patients include neurological and gastrointestinal issues such as headache, dizziness, dyspepsia (stomach discomfort), diarrhea, and nausea.
  • Common: Reactions occurring in 1 to 10 out of 100 patients include angina pectoris (chest pain), vomiting, rash, myalgia (muscle pain), and flushing.

Time-related regulatory data indicates that the common effect of headache often lessens or resolves as treatment continues beyond the initial period.

Serious Adverse Reactions and Safety Constraints

Official labeling documents less frequent but potentially serious adverse events. These reactions, often linked to the injectable formulation or post-marketing reports, include severe cardiac events like myocardial infarction, ventricular fibrillation, and asystole, along with serious neurological events such as stroke and seizures.

Regulatory documents also detail safety constraints for specific populations. The medicine is generally contraindicated or advised for use with caution in patients with severe hepatic or renal impairment. Caution is also specified for patients with pre-existing conditions like Coronary Artery Disease (CAD) or Myasthenia Gravis. Furthermore, a high-level safety constraint requires that oral Dipyridamole be temporarily held before specific cardiac diagnostic stress tests.

Overdose and Emergency Response

Overdose and When to Seek Help

The overdose profile for Dimole (Dipyridamole) is defined by an exaggeration of the drug's intended actions, primarily its vasodilatory effects, leading to significant hemodynamic manifestations. Officially documented clinical signs of an overdose include a warm feeling or flushes, sweating, restlessness, dizziness, and a profound feeling of weakness. The most critical physiological outcomes are severe hypotension (a substantial drop in blood pressure) and tachycardia (a rapid heart rate).

In the event of a suspected overdose or administration of a dose higher than recommended, regulatory bodies mandate that patients must seek immediate medical attention or contact a Poison Control Center. This urgency is driven by the potential for severe hemodynamic instability.

Overdose management is officially documented as primarily symptomatic and supportive. Procedures to be considered include gastric lavage. To address severe hypotension, treatment may involve the administration of a vasopressor drug. Furthermore, specific agents such as xanthine derivatives (e.g., aminophylline) are documented as measures that may potentially reverse the adverse hemodynamic effects of the overdose. Regulatory information also notes that dialysis is not likely to be of benefit because the drug is highly protein bound.

Therapeutic Uses of Dimole

What Dimole Treats: Main Uses and Benefits

Dimole is commonly used to help with symptoms related to physical discomfort. It is relevant in contexts involving heightened systemic burden. Its application may assist with symptoms associated with acute or episodic changes, and is applied in clinical settings that involve acute or unstable symptom patterns. Medications like Dimole are utilized in the therapeutic management of discomfort.

How Dimole Supports Symptom Management

Dimole is applied in situations involving certain distressing symptoms, generally used during phases when symptoms become more noticeable. It provides support that helps ease the overall symptom burden, and may assist with day-to-day comfort during symptomatic periods. This medicine is considered relevant in contexts marked by increased discomfort or tension, and may be part of symptomatic management when groups of symptoms appear suddenly or fluctuate.

supports general well-being during symptomatic phases.

Commonly used across conditions presenting with acute episodes, Dimole is relevant in settings where short-term symptomatic assistance is needed. It is applied in scenarios where additional management of discomfort is required, and may support the patient during difficult episodes by easing distress.


Quick Fact: Physical Discomfort is a central focus, relevant for easing symptoms that become more disruptive during flare-ups.

Regulatory References

  1. NIH MedlinePlus overview of Pain Management

Eligibility and Restrictions for Use

Dimole is officially intended for use by adults aged 18 years and over. The primary regulatory exclusion is a formal contraindication for any individual with documented hypersensitivity to the active substance, Dipyridamole, or any excipients contained in the formulation.


Age-Based Use Limitations

Age Group Regulatory Statement
Pediatric (Oral) Safety and effectiveness have not been established below the age of 12 years.
Pediatric (IV) Safety and effectiveness have not been established in patients younger than 18 years.

Condition-Based Use Restrictions

The official label mandates use with caution in specific populations. These include patients with severe coronary artery disease (such as unstable angina or recent myocardial infarction), hypotension (low blood pressure), and those with hepatic insufficiency (liver impairment). Special caution is also required for patients with Myasthenia Gravis.


Pregnancy and Lactation Status

Use during pregnancy is permitted only if clearly needed. Caution must be exercised during breastfeeding, as regulatory sources confirm the drug is excreted into human milk.

What should I know about interactions with other medicines?

Dimole Interactions with other medicines and products

The interaction profile of Dimole (Dipyridamole) is characterized by additive drug effects, specific transporter interference, and mandatory timing restrictions for diagnostic use, as documented in regulatory information.


Documented Interaction Patterns

Classification Interacting Agents / Restrictions
High-Risk Combinations Co-administration with Riociguat is restricted/contraindicated due to the risk of severe additive hypotension. Caution is required with Cholinesterase Inhibitors as Dipyridamole may counteract their effect, potentially aggravating myasthenia gravis.
Additive Bleeding Risk Concurrent use with other Antiplatelet Agents (e.g., Aspirin) and Anticoagulants (e.g., Warfarin) is associated with an officially recognized increased risk of bleeding or hemorrhage.
Exposure Modification Dipyridamole is an inhibitor of P-glycoprotein (P-gp) and BCRP efflux transporters, which can increase the systemic exposure of co-administered medicines that are substrates for these transporters.
Adenosinergic Agents Dipyridamole is reported to increase the plasma levels and enhance the cardiovascular effects of Adenosine and Regadenoson.

Procedural and Timing Constraints

Regulatory guidelines mandate procedural restrictions when Dipyridamole is used in diagnostic settings:

  • Oral Dipyridamole: Intake of oral tablets must be interrupted (held) within 48 hours prior to pharmacological stress testing with intravenous Adenosinergic Agents.
  • Methylxanthines: Substances like Caffeine and Theophylline must be discontinued for at least 24 hours prior to Dipyridamole stress testing, as they are documented to antagonize the intended vasodilatory effect.

Mechanism of Action

How Dimole Works

Dimole (Dipyridamole) acts through two distinct mechanistic domains that modulate platelet function and coronary vascular tone.


Modulating Platelet Activity via Cyclic Nucleotide Signaling

This action involves the inhibition of Phosphodiesterase (PDE) enzymes, specifically the PDE3 and PDE5 subtypes found in circulating platelets. By preventing the breakdown of the secondary messenger cAMP (cyclic Adenosine Monophosphate), the drug sustains high intracellular cAMP levels. This internal signaling change limits the mobilization of intracellular calcium, a necessary cofactor for platelet adhesion and aggregation, thereby reducing platelet aggregability.


Potentiating Coronary Blood Flow via Adenosine Homeostasis

The drug mediates vasodilation by acting as an inhibitor of the Equilibrative Nucleoside Transporter 1 ( ENT1). ENT1 typically clears adenosine from the extracellular space. By blocking this reuptake, Dipyridamole increases the local concentration of adenosine, which then acts on A2 A receptors on vascular smooth muscle. This A2 A receptor activation triggers a cascade that leads to the relaxation and widening of coronary resistance vessels, increasing local regional blood flow.

Dosage and Administration Information

How Dimole is Used

The administration of Dimole (Dipyridamole) is defined by its route and pharmaceutical form, which is structured around whether the medicine is used for maintenance or acute diagnostic procedures. There are two primary routes: oral for chronic therapeutic use and intravenous (IV) for clinical stress testing.


Administration Protocols

Oral Regimens

The medicine is supplied as immediate-release tablets and as a combination extended-release (ER) capsule. The standard prophylactic regimen for the single-agent tablet involves a dose of 75 to 100 mg taken four times daily (q.i.d.). The ER combination capsule, used for risk reduction, is prescribed for twice-daily (b.i.d.) use, taken in the morning and evening. A critical instruction for the ER capsule is that it must be swallowed whole and must not be opened, crushed, broken, or chewed to maintain its intended release profile.

Intravenous Use and Special Conditions

For diagnostic testing, the IV injectable solution is administered as a single, weight-adjusted dose, typically 0.56 mg/kg, delivered as a controlled infusion over a 4-minute period. The solution requires professional dilution prior to use and should not be mixed with other medications in the same container. Oral dipyridamole-containing products are typically discontinued for at least 48 hours before this diagnostic procedure. Furthermore, the administration of Dipyridamole is not established for pediatric patients under 12 years for oral forms or under 18 years for the IV route.

Recent Clinical Evidence

Research evidence / Overview of studies for Dimole

This overview describes the research evidence for Dimole (Dipyridamole) as documented in official and peer-reviewed scientific literature. The purpose is to summarize the types of studies conducted, the outcomes research examined, and the recognized limits of the current data.


Evidence for Use in Preventing Clots with Heart Valve Replacement

The research for this use of Dimole was evaluated in studies that examined its inclusion alongside a primary anticoagulant in adults who had undergone surgery to receive a mechanical heart valve. Researchers monitored the occurrence of major vascular outcomes, primarily focusing on the frequency of thromboembolic events (blood clots) forming around the valve.

Studies reported measured patterns in the frequency of these events when Dimole was included in the research regimen compared to the standard anticoagulant regimen alone. The documented findings focused on Dimole's inclusion alongside the primary anticoagulant; research examining Dimole alone in this setting is limited. Furthermore, there is limited information for long-term outcomes measured against newer therapeutic standards.


Evidence for Secondary Prevention of Stroke and TIA

Research for this indication primarily centers on the extended-release formulation of Dipyridamole when combined with aspirin. This combination product was studied for long-term evaluation in patients who had recently experienced a minor stroke or a Transient Ischemic Attack (TIA).

The evidence is derived from large-scale, multinational Randomized Controlled Trials (RCTs) and subsequent systematic reviews. Studies primarily examined outcomes such as the recurrence of stroke, non-fatal myocardial infarction (MI), and vascular death. The strongest data show patterns related to the extended-release combination product; research evidence quality varies across studies when examining the immediate-release formulation of Dimole used alone.


What is Still Uncertain About Dimole Research

Research highlights what is known and what is still uncertain across the evidence landscape. A primary area of uncertainty is the role of immediate-release dipyridamole when used alone for preventing stroke recurrence; the stronger evidence is primarily for the extended-release combination product with aspirin. Comparative evidence against many contemporary treatments is also lacking, as much of the foundational research is older.

Key Studies & References

  1. Antiplatelet and anticoagulation for patients with prosthetic heart valves (Cochrane Review)
  2. ACR–ACNM–NASCI–SNMMI–SPR–STR Practice Parameter for the Performance of Cardiac Scintigraphy (Dipyridamole use for Myocardial Perfusion Imaging)

Frequently Asked Questions (FAQ)

Common questions about Dimole (FAQ)


Q: How long does it typically take to feel the effects of Dimole?

Regulatory information indicates how quickly the drug is absorbed into the bloodstream. For the conventional oral tablets, the concentration of the drug in the blood typically reaches its peak in about 75 minutes to 2.5 hours after being taken. This is a measure of absorption and not an indication of when a patient will sense a clinical effect.


Q: Can Dimole be taken by someone who is vegetarian?

Some formulations of Dimole, particularly certain capsule shells, contain gelatin, which is often animal-derived. Other products may contain lactose monohydrate as an inactive ingredient. For a specific product, the full list of inactive ingredients can be reviewed for specific concerns.


Q: Are there any specific foods that should be avoided when taking Dimole?

Specific foods are not widely prohibited when taking the conventional tablet. However, official guidance for the standard Dipyridamole tablet describes taking it on an empty stomach (one hour before or two hours after meals). The extended-release capsules can typically be taken with or without food.


Q: Can people who are lactose intolerant use Dimole?

Some oral formulations, including certain tablets and capsules, are described in official documents as containing lactose or sucrose. For patients with known rare hereditary problems involving sugar intolerance, official documents mention caution for use of these specific forms.


Q: Does taking Dimole affect sleep patterns?

Official regulatory labels do not list insomnia or changes in sleep patterns as a common side effect of Dimole. However, the active ingredient has been examined in some research studies as an investigational agent for conditions related to sleep, such as Restless Leg Syndrome.


Q: Why is Dimole usually prescribed for a short amount of time?

The use of Dimole depends on the condition it is addressing. For chronic therapeutic uses, such as preventing blood clots after a heart valve replacement, it is often intended as a long-term medication. Regulatory information notes that stopping the medicine may result in the rapid return of the condition being managed.


Q: Is Dimole considered a controlled substance?

No, according to the official classification by U.S. regulatory bodies, the active ingredient in Dimole (Dipyridamole) is not classified as a controlled medication.


Q: What happens if a dose of Dimole is missed?

Official documents describe a general guideline for managing a missed dose. Typically, if it is almost time for the next scheduled dose, the missed dose is skipped. The guidance emphasizes that the next dose should be taken at the regular time, and doubling up on a dose is not recommended in regulatory documents.


Q: Is there a generic version of Dimole available?

Yes, regulatory and pharmaceutical information confirms that generic versions of the active ingredient, Dipyridamole, are available for prescription.


Q: Can Dimole be used by the elderly population?

Studies indicate that no specific dose adjustment is typically required for older adult patients. However, official labeling describes the need for caution for use in this population due to a potential increased sensitivity to certain effects, such as hypotension (low blood pressure).


Q: Can Dimole be taken on an empty stomach?

The conventional Dipyridamole tablet is generally taken in accordance with official guidance on an empty stomach—at least one hour before or two hours after a meal. This timing is described in regulatory documents as promoting the drug's intended absorption profile, although extended-release capsules can be taken with or without food.


Q: How long does Dimole stay in the body after the last dose?

Regulatory pharmacokinetic data indicates that the active ingredient is eliminated from the body in a two-stage process. The terminal elimination half-life, which measures the time required for half the drug to leave the body, is approximately 10 to 12 hours for the tablets.


Q: Are there any warnings about driving or operating machinery while using Dimole?

Yes, official product information notes that Dipyridamole may cause side effects such as dizziness or lightheadedness. Driving or operating heavy machinery should be avoided if these effects are experienced.


Q: Does Dimole contain any substances derived from animals?

Some formulations, especially the capsules, may contain gelatin, which is typically derived from animal sources. The full list of inactive ingredients (excipients) can be reviewed for specific dietary concerns.


Q: Is the effectiveness of Dimole measured by changes in certain lab tests?

While the patient's condition is primarily monitored clinically, regulatory information describes that certain laboratory tests, such as monitoring liver enzyme levels or occasionally assessing the drug's effect on platelet function, may be used during treatment.


Q: What is the main difference between Dimole and similar medicines?

Official descriptions classify Dimole as a dual-acting agent. It functions as both an antiplatelet agent (reducing blood clot formation) and a coronary vasodilator (widening blood vessels). This dual role is described as involving two distinct mechanistic domains that modulate platelet function and vascular tone.


Q: Does Dimole interact with common cold or flu remedies?

Regulatory documents emphasize the need for caution regarding the use of over-the-counter nonprescription medications, including cold or flu remedies. This is particularly important for products that contain interacting ingredients like aspirin or NSAIDs.


Q: Is the research evidence for Dimole considered strong?

The drug's approval is based on findings from Randomized Controlled Trials (RCTs). The strongest evidence base is often cited for the extended-release combination product with aspirin used for the secondary prevention of stroke.


Q: Do any official documents describe potential long-term risks of Dimole?

Official documents detail potential serious adverse events and warnings for specific populations, such as those with severe liver problems. Preclinical (animal) studies at therapeutic doses have generally been noted to show no significant long-term findings.


Q: Does Dimole interact with any common vitamins or supplements?

Official guidance notes that all vitamins, nutritional supplements, and herbal products should be considered, as adjustments or specific monitoring may be necessary due to potential interactions.


Q: How does Dimole compare to similar treatments mentioned in official research?

Official research, particularly in the context of stroke prevention, has compared the extended-release combination product against its individual components. These studies indicate that the combination product provides the most significant reduction in stroke risk compared to using the active ingredients alone.

How should Dimole be stored and disposed of?

How to Store and Dispose of Dimole?

The storage and disposal instructions for Dimole (Dipyridamole) are strictly defined by regulatory labeling to maintain product stability and ensure public safety.

Storage Requirements

  • Temperature: Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Do not allow the medication to freeze.
  • Protection: The product must be protected from excessive moisture and kept away from excessive heat. The container should be kept tightly closed.
  • Child Safety: The medication must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Guidelines

Disposal of any unused or expired Dimole must be performed according to local regulations and official waste handling programs. The medication should not be flushed down a toilet or sink unless specific instructions on the labeling permit this.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dimole found in:

A-Z Index: